Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2023: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2022: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2021: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2020: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2019: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
Outline of Final Research Achievements |
This study aimed that analysis of oral squamous cell carcinoma using the Patient-derived xenograft (PDX) models which was established by us. 3 of 17 primary transplants were successful. The second transplantation was successful in 2 out of 3 cases, and the third transplantation was successful in 2 out of 2 cases. We analyzed mutation analysis in tumor of PDX models and patients which was donor. We detected 73 mutations and 371651 mutations in PDX models and donor patients. We were able to establish PDX model mouse derived from OSCC. Furthermore, the tumor of PDX models reflected the genetical features in donor patients.
|